The validation of disinfectant efficacy within cleanroom environments has become an increasingly critical aspect of pharmaceutical manufacturing, particularly following the 2022 revision of the European Union’s Good Manufacturing Practice (EU GMP) Annex 1(1). This revision, which came into effect in August 2023, introduced more stringent expectations for contamination control, placing a renewed emphasis on the validation of disinfectants in the specific manner of their use and on the actual surfaces present within controlled environments.
Annex 1 now explicitly mandates that disinfectants must be validated via realistic evaluations that incorporate cleanroom-relevant surfaces and microorganisms isolated from the manufacturing environment.
Section 4.34 of the revised Annex 1 states: “The disinfection process should be validated. Validation studies should demonstrate the suitability and effectiveness of disinfectants in the specific manner in which they are used and on the type of surface material, or representative material if justified...”
This directive underscores the importance of aligning validation practices with actual operational procedures, and this may include the application of disinfectants via wipes or mops and on surfaces such as stainless steel and polymeric materials relevant to a cleanroom facility.
Despite the clarity of the regulatory requirement, Annex 1 does not prescribe specific test methods or pass criteria, leaving end-users with the responsibility to select appropriate standards and design validation studies that reflect their facility’s contamination control strategy. This has led to widespread reliance on existing test standards such as EN 13697(2), EN 16615(3), ASTM E2967(4), ASTM E2362(5), and regulatory guidance such as USP <1072>(6), each offering distinct methodologies, guidance and scopes.
EN 13697 is a European standard that evaluates the bactericidal and fungicidal activity of disinfectants on non-porous surfaces without mechanical action. It provides quantitative log reduction values, typically requiring a 4-log reduction for vegetative bacteria and a 3-log reduction for fungi. While robust and widely recognised, EN 13697 does not simulate the mechanical action of wiping or mopping, which can be integral to cleanroom disinfection practices. Moreover, its use of high microbial inocula and standardised surfaces such as stainless steel may not accurately reflect the low bioburden and diverse materials found in cleanrooms. EN 13697 serves as valuable data for assessing disinfectant efficacy and its methodology is frequently adapted, incorporating aspects like extra surfaces, facility-specific organisms, and reduced inoculation levels for cleanroom validation purposes.
To address the limitations of EN 13697, EN 16615 was developed as a more realistic method for evaluating disinfectant wipes. Known as the “four-field test,” EN 16615 involves contaminating one quadrant of a surface and wiping across adjacent sterile fields in a single pass. This method assesses both microbial reduction and the potential for cross-contamination, making it particularly relevant for cleanroom applications. The test incorporates mechanical action using a standardised weight to simulate wiping pressure and provides dual acceptance criteria: a 5-log reduction for bacteria and a 4-log reduction for yeast on the contaminated field and a maximum of 50 colony-forming units (CFU) on the clean fields.
However, EN 16615 also presents challenges. Its scope is limited to bacteria and yeast, excluding sporicidal and virucidal claims. The standard specifies PVC surfaces and a particular wipe substrate that may not be suitable for cleanroom use due to shedding. Furthermore, the prescribed bi-directional wiping motion does not reflect the unidirectional, overlapping techniques commonly employed in cleanroom environments. As previously discussed with the adaptions commonly applied to EN13697 methodology, these discrepancies then necessitate adaptations, such as using cleanroom-compatible wipe materials, modifying the wiping technique, and incorporating facility-specific surfaces and microbial isolates. End-users often refer to USP <1072> to guide such modifications, which allows for a more tailored approach to disinfectant validation.
ASTM standards offer alternative methodologies. ASTM E2362 evaluates the antimicrobial effectiveness of pre-saturated towelettes on hard, non-porous surfaces. It is a qualitative test that determines the presence or absence of microbial growth after treatment, using organisms such as Staphylococcus aureus, Pseudomonas aeruginosa, Mycobacterium bovis, and Trichophyton mentagrophytes. While useful for product registration and demonstrating broad-spectrum efficacy, ASTM E2362 lacks quantitative data and does not assess cross-contamination.
ASTM E2967, on the other hand, introduces the ‘Wiperator’ device to simulate orbital wiping motion under controlled conditions. This method evaluates both the removal of microbial contamination and the transfer of microbes to clean surfaces. It provides quantitative data on CFU reduction and transfer, offering insights into the physical cleaning performance of disinfectant wipes. However, its limited microbial scope and reliance on specialised equipment may restrict its applicability in pharmaceutical cleanrooms.
USP <1072> serves as a valuable guidance document for disinfectant validation in pharmaceutical environments. It emphasises the importance of testing disinfectants under actual use conditions, on facility-specific surfaces, and against both standard and environmental isolates. USP <1072> recommends a 3-log reduction for vegetative bacteria and a 2-log reduction for spores as acceptable efficacy criteria. While it does not prescribe specific test methods, it supports the adaptation of existing standards to meet cleanroom requirements, providing a flexible framework for validation studies.
Recognising the limitations of existing standards, Ecolab developed the Validex™ programme(7), a harmonised disinfectant efficacy testing method tailored to cleanroom environments. Launched in 2018, Validex™ addresses the gaps in global standards by offering a reproducible, scientifically robust approach that aligns with regulatory expectations from the FDA, EMA, and PIC/S. The programme comprises two complementary methods: one without mechanical action based on EN 13697 principles, and another incorporating mechanical action inspired by EN 16615 and USP <1072>. The Validex™ wiping method represents a scientifically rigorous evaluation of disinfectant wipe efficacy testing, developed to better reflect real world cleanroom practices while maintaining regulatory robustness. Building on EN 16615, the method systematically evaluates and optimizes critical experimental variables that influence both microbial kill and organism transfer during wiping. Extensive method development studies were conducted to define appropriate starting inoculum levels for different species of microorganism, accounting for differential survival during drying and ensuring reliable demonstration of required log reductions. Inoculum application techniques, interfering substance ratios, drying conditions, and surface materials were experimentally assessed to minimize variability and prevent false failures. Mechanical action was refined by replacing the standard high mass test block with a calibrated weight, representative of operator applied pressure. The method incorporates realistic wiping parameters including unidirectional overlapping strokes, wipe folding, pressure, layer number, and saturation volume based on substrate absorbency and size. The method explicitly differentiates between microbial inactivation and physical transfer by incorporating carryover assessment fields, providing a more comprehensive measure of wipe performance. Neutralization efficacy, swab recovery, surface reprocessing, and analyst repeatability were independently validated to confirm method suitability, accuracy, and reproducibility. Collectively, these scientifically driven refinements result in a robust, repeatable, and cleanroom relevant efficacy test method that more accurately reflects practical disinfectant wipe use while meeting regulatory expectations. The Validex™ wiping method has been conducted against relevant organisms such as Staphylococcus epidermidis, Pseudomonas aeruginosa, Candida albicans, and Bacillus subtilis spores. Acceptance criteria are set at a 3-log reduction for vegetative bacteria and a 2-log reduction for fungi and spores within a 5–10 minute contact time (dependent on organism-surface combination).
By incorporating both chemical efficacy and mechanical action, Validex™ provides a comprehensive data package validated through accredited laboratories. It supports end-users in meeting Annex 1 requirements by demonstrating disinfectant performance under real-world application. The programme’s flexibility allows for the inclusion of facility-specific surfaces and isolates, enabling a risk-based approach to surface selection and microbial challenge.
In conclusion, the revised EU GMP Annex 1 has elevated the importance of disinfectant validation in cleanrooms, demanding evidence of efficacy that reflects actual use conditions.
While existing standards such as EN 13697, EN 16615, ASTM E2362, ASTM E2967, and guidance documents such as USP <1072> offer valuable frameworks, each present limitations when applied to pharmaceutical environments. The Validex™ programme emerges as a harmonised solution, integrating the strengths of these standards while addressing their shortcomings. By aligning with regulatory expectations and simulating cleanroom practices, Validex™ enables manufacturers to confidently validate their disinfectants, ensuring robust contamination control and compliance with global GMP requirements.
